Omnicell

SEPTEMBER 5, 2022

Ken Perez VP of Healthcare Policy Omnicell The Democrats’ recent sweep of the United States Senate Georgia runoff elections means the Democrats will control both chambers of Congress as well as the White House for the first time since 2010.

Vaccines 52

Vaccines Omnicell Documentation Immunization 52

Roots Analysis

OCTOBER 30, 2023

The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).

Vaccines 40

Vaccines Immunization Packaging Pharmaceutical Companies 40

pharmaphorum

APRIL 7, 2021

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. It has brought a lot of good things working together and networking has led to unbelievable successes,” he added, noting the rapid development of vaccines by companies such as Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University.

Chemotherapy 91

Chemotherapy Hospitals Vaccines 91

European Pharmaceutical Review

SEPTEMBER 18, 2023

Events, as well as talks from industry leaders and networking opportunities, will be coordinated by a new ‘Scottish Advanced Therapy Medicinal Products (ATMP) and Vaccines Network’ to aid individuals and the wider industry across the north of the UK. Since 2010, the sector has secured eight percent growth each year.

Vaccines 117

Vaccines 117

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. Figure 1: OECD average of public spending on health (Source: OECD ). per person in the US) and is widely adopted.

Vaccines 130

Vaccines 130

pharmaphorum

SEPTEMBER 18, 2020

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 Its oncology treatment Arimidex lost exclusivity in the US in 2009, accounting for a sales decrease of 86%, as published in the 2010 annual report. Pascal Soriot.

Pharmaceutical Companies 116

Pharmaceutical Companies Pharmaceutical Companies Vaccines FDA 116

pharmaphorum

SEPTEMBER 8, 2020

When the day hopefully comes where a vaccine is widely available, we will be relieved of the great stress and uncertainty of this time. 4 Global oncology spending in 2010, 2015, and 2020, by region (in billion U.S. Available from : [link] [Last accessed: September 2020]. 3 Wilking N, Lopes G, Meier K, et al. Touch Oncology.

Chemotherapy 99

Chemotherapy Patient Care Vaccines FDA 99

European Pharmaceutical Review

JANUARY 31, 2023

billion in poorer countries access to full medicine portfolio… MPP has signed 34 licences for various health technologies and facilitated access to 30 billion doses of treatments since 2010. NEWS: Pfizer offers 1.2 These successes have helped to define its new strategy.

Communication 105

Communication Vaccines 105

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Hospitals 105

Hospitals Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

pharmaphorum

JANUARY 27, 2023

The recent reversal of China’s “zero Covid” policy, at a time when the country still lacks optimal vaccine coverage, has also created another unknown, in terms of global supply and demand forecasting. He previously held regional leadership roles at Sandoz between 2005 and 2010.

Packaging 105

Packaging Vaccines 105

European Pharmaceutical Review

MARCH 11, 2024

For example, rising ambient temperatures and ingress of mould from items entering cleanrooms, has resulted in some vaccine and pharmaceutical companies in Europe experiencing increased contamination. Ahmed et al.

Sterile Compounds 98

Sterile Compounds Compounding Packaging Pharmaceutical Companies 98

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 98

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

FEBRUARY 23, 2023

His prior appointments include senior global R&D, and quality leadership roles across diverse drug, device and biologics portfolios for the likes of Baxter Healthcare, Eli Lilly and Evans Vaccines. Edward actively publishes and is a leading authority on pharmaceutical microbiology, risk, aseptic and sterile manufacturing.

Dosage 111

Dosage Vaccines 111

pharmaphorum

MARCH 2, 2021

The Conservative Party has strong ties with pharma and life sciences and has been backing the industry since David Cameron led it back to power in 2010 with a range of policies aimed at boosting research and investment. billion investment in equity finance in the sector in 2020.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

DECEMBER 26, 2023

Single-use bioprocessing technologies enabling more rapid vaccines production [Internet]. Available from: [link] About the author Kai Lipinski, PhD joined Vibalogics, now ReciBioPharm, in 2010 as Head of Cell Culture and Virus Production. Available from: [link] Nielsen J, Tillegreen CB, Petranovic D. Trends in Biotechnology.

Packaging 98

Packaging Vaccines 98

pharmaphorum

OCTOBER 12, 2022

Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Just as mRNA and COVID-19 showed the world that it’s possible to develop vaccines much faster, Del Bourgo explains, AI can help us develop new genomic medicines in a more efficient way.

Immunization 105

Immunization Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

JANUARY 19, 2023

Waiting lists have grown not because of COVID, but [have been] growing consistently since 2010.” The vaccine programme is the best example,” Lord Prior said. BioNTech, or Pfizer, or others – within nine months, we had a vaccine, ran clinical trials at scale, cheaply and quickly.” It’s our last throw,” Lord Prior explained.

Hospitals 96

Hospitals Vaccines 96

pharmaphorum

OCTOBER 24, 2022

Exemptions include exceptional central procurements, centrally procured vaccines, small company sales, and low-value sales (when the NHS list price is less than £2). It’s been around for some time, having first been introduced in 2010 on a regional basis. As ever, the controversy is about the trade-offs and just where to draw the line.

Vaccines 75

Vaccines 75

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies Vaccines 64

pharmaphorum

OCTOBER 12, 2021

billion in 2010. At the moment there’s no world on a possible replacement for Stoffels, who oversees the pharma industry’s third-largest R&D budget at more than $12 billion in 2020, up from $6.8

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccines 98

Vaccines Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccines 96

Vaccines Pharmaceutical Companies Pharmaceutical Companies Immunization 96

pharmaphorum

APRIL 4, 2022

Until now, AXA Investment Managers has been focused more on the delivery end of health care – health centres and private hospitals, for example – but the new strategy is directed at four key areas, including biopharma, vaccines, medical devices and diagnostics companies.

Vaccines 59

Vaccines Insurance Hospitals 59

PharmaShots

FEBRUARY 21, 2023

Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. Under its radiopharmaceutical segment, OncoTherapy is developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

Pharmaceutical Technology

MAY 15, 2023

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Mayo Clinic 52

Mayo Clinic Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 21, 2022

In 2010, only eight big pharma companies had an access strategy for low- and middle-income countries, but today, 17 of the biggest 20 companies do. According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs. Drug pricing and gouging.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 52

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Hospitals 52

Hospitals Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines FDA 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 52

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 24, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Hospitals 52

Hospitals Pharmaceutical Companies Pharmaceutical Companies Immunization 52